A5044931474- Diabetes Treatment and Management
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Diabetes Management and Research
- Chronic Kidney Disease and Diabetes
- Atrial Fibrillation Management and Outcomes
- Pharmacology and Obesity Treatment
- Pharmaceutical Practices and Patient Outcomes
- Potassium and Related Disorders
- Dialysis and Renal Disease Management
- Medication Adherence and Compliance
- Cardiovascular Health and Risk Factors
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Education
- Cardiovascular Function and Risk Factors
- Electrolyte and hormonal disorders
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrhythmias and Treatments
- Venous Thromboembolism Diagnosis and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Central Venous Catheters and Hemodialysis
- Clinical practice guidelines implementation
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Chronic Disease Management Strategies
Johns Hopkins University
2017-2025
Madison Group (United States)
2021
Clinical Research Consortium
2021
Welch Foundation
2018-2020
Jungheinrich (Germany)
2017-2019
University of Baltimore
2017-2018
University of Wisconsin–Madison
2013-2016
Seoul National University Hospital
2008
Seoul National University
2005-2007
<h3>Importance</h3> It is uncertain whether and when angiotensin-converting enzyme inhibitor (ACE-I) angiotensin II receptor blocker (ARB) treatment should be discontinued in individuals with low estimated glomerular filtration rate (eGFR). <h3>Objective</h3> To investigate the association of ACE-I or ARB therapy discontinuation after eGFR decreases to below 30 mL/min/1.73 m<sup>2</sup>with risk mortality, major adverse cardiovascular events (MACE), end-stage kidney disease (ESKD)....
Approximately 1 million patients in the United States with type 2 diabetes mellitus and mild-to-moderate kidney disease do not receive guideline-directed therapy metformin. This may reflect uncertainty regarding risk of acidosis chronic disease.
The optimal approach to screening and diagnosis of prediabetes diabetes in youth is uncertain.We conducted a cross-sectional analysis 14 119 aged 10 19 years the 1999-2016 NHANES. First, we examined performance American Diabetes Association risk-based criteria. Second, evaluated current clinical definitions based on hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), either HbA1c or FPG, both FPG (confirmatory definition) identify at high cardiometabolic risk.Overall, 25.5% US (10.6...
Obesity is a global public health challenge and strongly associated with type 2 diabetes (T2D), but its burden effects are not well understood in people 1 (T1D). Particularly, the link between obesity chronic kidney disease (CKD) T1D poorly characterized.
Background and objectives All randomized trials of direct oral anticoagulants in atrial fibrillation excluded patients with severe kidney disease. The safety effectiveness across the range eGFR real-world settings is unknown. Our objective to quantify risk bleeding benefit ischemic stroke prevention for compared warfarin without CKD. Design, setting, participants, & measurements We created a propensity score–matched cohort 3206 anticoagulant use using from October 2010 February 2017 an...
Chronic kidney disease (CKD) increases risk of cardiovascular (CVD). Less is known about how CVD associates with future failure replacement therapy (KFRT).
Background Low socioeconomic status (SES) is associated with a higher risk of heart failure (HF). The contribution individual and neighborhood SES to the prognosis quality care for HF reduced ejection fraction not clear yet has important implications. Methods Results We examined 728 participants ARIC (Atherosclerosis Risk in Communities) study (mean age, 78.2 years; 34% Black participants; 46% women) hospitalized (ejection <50%) between 2005 2018. assessed associations education, income,...
Significance Statement Despite reports of hematuria and proteinuria with rosuvastatin use at the time its approval by US Food Drug Administration (FDA), current labeling mentions dose reduction (maximum daily 10 mg) only for patients severe CKD. In this real-world study, 44 % CKD were prescribed a higher than recommended FDA. Compared atorvastatin, was associated slightly increased risk in dose-dependent manner kidney failure replacement therapy; cardiovascular benefits similar. These...
BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between US Food and Drug Administration European Medicines Agency patients with atrial fibrillation. Optimal in chronic disease remains unknown. METHODS: With use deidentified electronic health record data from Optum Labs Data Warehouse, fibrillation stage 4/5 initiating 2013 2021 were identified. Risks bleeding stroke/systemic embolism compared by dose (5 versus 2.5 mg), adjusted baseline...
Abstract Aims To characterize trends in obesity and prescriptions for glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) across body mass index (BMI) categories among US youth adults with type 1 diabetes (T1D) from 2008 to 2023. Materials Methods Patients T1D were identified using a validated algorithm de‐identified electronic health record (EHRs) data 33 systems. BMI based on age‐ sex‐specific percentiles (2–19 years) World Health Organization cut points (≥20 years). Trends GLP1‐RA...
OBJECTIVE To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1a), consequent impact on adverse outcomes, including hospitalizations emergency department (ED) visits. RESEARCH DESIGN AND METHODS This retrospective cohort study used MarketScan Commercial data (2016–2021). The included nonpregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1a therapy. Participants were continuously enrolled...
<p dir="ltr">Objective To examine the associations between patient out-of-pocket (OOP) costs and non-adherence to glucagon-like peptide-1 receptor agonists (GLP-1a), consequent impact on adverse outcomes including hospitalizations emergency department (ED) visits. Research Design Methods This retrospective cohort study utilized MarketScan® Commercial data (2016 - 2021). The included non-pregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1a therapy. Participants...
<p dir="ltr">Objective To examine the associations between patient out-of-pocket (OOP) costs and non-adherence to glucagon-like peptide-1 receptor agonists (GLP-1a), consequent impact on adverse outcomes including hospitalizations emergency department (ED) visits. Research Design Methods This retrospective cohort study utilized MarketScan® Commercial data (2016 - 2021). The included non-pregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1a therapy. Participants...
Significance Statement Because race and sex affect serum creatinine levels independently of GFR, the Food Drug Administration’s previous creatinine-based metformin contraindication may have inadvertently caused racial disparities in prescription among patients with diabetes moderate kidney dysfunction. It is unknown whether these were mitigated after a 2016 labeling change to an eGFR-based contraindication. The authors found that before change, eGFR 30–44 ml/min per 1.73 m 2 , Black men...
OBJECTIVE Patients with diabetes and chronic kidney disease (CKD) have increased susceptibility to acute injury (AKI), but mechanisms are unclear. We investigated the association of glycemic control risk AKI. RESEARCH DESIGN AND METHODS In two observational cohorts U.S. (Geisinger Health System, Danville, PA) Swedish (Stockholm CREAtinine Measurements [SCREAM] project, Stockholm, Sweden) adults type 2 confirmed CKD stages G3–G5 undergoing routine care, we evaluated associations between...
Background Despite interest in low-grade albuminuria and poor clinical outcomes, evidence from a large-scale population is lacking. Therefore, we identified the association of within normal range with all-cause cardiovascular (CV) mortality. Methods After excluding individuals urine albumin-creatinine ratio (ACR) ≥30 mg/g ( n =6094), this cohort study analyzed 43,396 adults who participated National Health Nutrition Examination Survey (1999–2016). Participants were divided into four...
The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people lower socioeconomic status (SES); however, it is unknown whether use differs by SES.We included adults obesity and used prescription from 2009-2018 US National Health Nutrition Examination Survey. We examined associations between a composite measure SES...